X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com/news-release/2024/04/06/2858811/18362/en/New-REDUCE-IT-Analyses-Show-VASCEPA-VAZKEPA-Icosapent-Ethyl-Benefit-in-High-Risk-Cardiovascular-Disease-Patient-Subgroups.html
https://www.globenewswire.com/news-release/2024/04/03/2856860/18362/en/Amarin-Provides-Update-on-VAZKEPA-Icosapent-Ethyl-Intellectual-Property-Portfolio-in-Europe.html
https://www.globenewswire.com/news-release/2024/03/25/2851539/0/en/Smith-Nephew-teams-up-with-UFC-to-be-first-ever-Preferred-Sports-Medicine-Technology-Partner.html
https://www.globenewswire.com/news-release/2024/03/25/2851545/18362/en/Research-Evaluating-Benefits-of-VASCEPA-VAZKEPA-icosapent-ethyl-to-be-Presented-at-the-American-College-of-Cardiology-s-ACC-Annual-Scientific-Session-Expo.html
https://www.indianpharmapost.com/news/strides-launches-icosapent-ethyl-acid-soft-gel-capsules-in-partnership-with-amneal-14958
https://www.globenewswire.com//news-release/2023/11/12/2778635/18362/en/New-REDUCE-IT-Analyses-Show-VASCEPA-icosapent-ethyl-Associated-with-29-Percent-Relative-Risk-Reduction-Compared-with-Placebo-in-Prespecified-Subgroup-of-Patients-with-Metabolic-Syn.html
https://www.globenewswire.com//news-release/2023/10/26/2767462/18362/en/Latest-Research-Evaluating-VASCEPA-VAZKEPA-icosapent-ethyl-and-Subgroups-from-the-REDUCE-IT-Landmark-Outcomes-Trial-to-be-Presented-at-the-American-Heart-Association-AHA-Scientific.html
https://www.globenewswire.com/news-release/2023/08/09/2722118/18362/en/Amarin-Provides-Pricing-Reimbursement-Updates-for-VAZKEPA-icosapent-ethyl-in-The-Netherlands-and-Italy.html
https://www.globenewswire.com/news-release/2023/08/08/2720436/18362/en/Amarin-And-Neopharm-Announce-Exclusive-Commercialization-Agreement-for-VAZKEPA-Icosapent-Ethyl-in-Israel.html
https://www.globenewswire.com/news-release/2023/08/07/2719579/18362/en/Scottish-Medicines-Consortium-Accepts-VAZKEPA-icosapent-ethyl-to-Help-Reduce-Cardiovascular-Risk-for-Patients-in-Scotland-1.html
https://www.globenewswire.com/news-release/2023/07/26/2711275/18362/en/Latest-Research-Evaluating-Clinical-Benefits-of-VASCEPA-VAZKEPA-icosapent-ethyl-to-be-Presented-at-the-European-Society-of-Cardiology-ESC-Congress.html
https://www.globenewswire.com/news-release/2023/07/25/2710859/18362/en/Amarin-Receives-Positive-Recommendation-from-Spanish-Drug-Pricing-Committee-for-National-Reimbursement-of-VAZKEPA-icosapent-ethyl-in-Spain.html
https://www.globenewswire.com/news-release/2023/07/18/2706852/18362/en/Amarin-Implements-Organizational-Restructuring-to-Strengthen-the-Company-While-Driving-Patient-Access-to-VASCEPA-VAZKEPA-Globally.html
https://www.globenewswire.com/news-release/2023/06/21/2692114/18362/en/Amarin-Announces-Vascepa-Icosapent-Ethyl-Approved-to-Reduce-Cardiovascular-Risk-in-the-Kingdom-of-Saudi-Arabia-KSA.html
https://www.globenewswire.com/news-release/2023/06/01/2680082/18362/en/Amarin-Partner-EddingPharm-Receives-Regulatory-Approval-for-Vascepa-Icosapent-Ethyl-in-Mainland-China.html
https://www.globenewswire.com/news-release/2023/05/12/2667968/18362/en/Amarin-Highlights-New-Data-Providing-Potential-Mechanistic-Insight-into-Vascepa-Vazkepa-Icosapent-Ethyl-Reduction-of-Cardiovascular-Events.html
https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-vazkepar-icosapent-ethyl-approved-israels
https://www.globenewswire.com/news-release/2023/04/04/2640591/18362/en/Amarin-Announces-VAZKEPA-Icosapent-Ethyl-Approved-by-Israel-s-Ministry-of-Health.html
https://www.globenewswire.com/news-release/2023/03/05/2620629/18362/en/Amarin-Announces-New-REDUCE-IT-Data-at-ACC-23-WCC-Showing-Benefit-of-VASCEPA-VAZKEPA-Icosapent-Ethyl-in-High-Risk-Patients-with-a-Recent-Acute-Coronary-Syndrome-Event.html
https://www.globenewswire.com/news-release/2023/02/28/2617048/18362/en/Amarin-and-CSL-Seqirus-Announce-Exclusive-License-and-Distribution-Agreement-to-Commercialize-VAZKEPA-Icosapent-Ethyl-in-Australia-and-New-Zealand.html
https://www.reuters.com/legal/hikma-accuses-amarin-suppressing-generic-versions-heart-pill-2023-02-22/
https://www.globenewswire.com/news-release/2023/01/27/2596924/18362/en/Amarin-Announces-VAZKEPA-Icosapent-Ethyl-Approved-By-Medsafe-In-New-Zealand.html
https://www.globenewswire.com//news-release/2022/12/07/2569329/18362/en/Amarin-Announces-VAZKEPA-icosapent-ethyl-Receives-Regulatory-Approval-in-Switzerland.html
https://www.globenewswire.com/news-release/2022/11/15/2555943/18362/en/Amarin-Announces-VAZKEPA-icosapent-ethyl-Approved-by-the-Therapeutic-Goods-Administration-TGA-in-Australia.html
https://www.globenewswire.com/news-release/2022/11/07/2549664/18362/en/Amarin-Highlights-Key-Data-Presented-at-American-Heart-Association-2022-Scientific-Sessions-for-VASCEPA-VAZKEPA-icosapent-ethyl-and-Patient-Care.html
https://www.pharmaceutical-technology.com/news/amarin-makes-moves-towards-global-expansion-of-vazkepa/
https://www.globenewswire.com/news-release/2022/08/28/2505567/18362/en/New-REDUCE-IT-Data-Show-VASCEPA-VAZKEPA-icosapent-ethyl-Reduced-Cardiovascular-Events-in-Patients-Who-Are-Current-or-Former-Smokers.html
https://www.globenewswire.com/news-release/2022/08/15/2498154/18362/en/Latest-Research-Evaluating-VASCEPA-VAZKEPA-icosapent-ethyl-and-Subgroups-from-the-REDUCE-IT-Landmark-Outcomes-Trial-to-be-Presented-at-the-European-Society-of-Cardiology-ESC-Congre.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209499
https://www.globenewswire.com/news-release/2022/07/13/2478943/18362/en/NICE-Issues-Final-Guidance-for-Reimbursement-Making-VAZKEPA-icosapent-ethyl-Available-Across-the-NHS-in-England-Wales.html
https://www.trialsitenews.com/a/amarin-releases-post-hoc-data-from-reduce-it-sub-study-showing-that-vascepa-had-little-impact-on-lipid-inflammatory-biomarkers-compared-to-placebo-ef80b828
https://www.globenewswire.com/news-release/2022/06/30/2472521/18362/en/REDUCE-IT-Exploratory-Post-Hoc-Biomarker-Sub-Analysis-Shows-Relatively-Small-Changes-in-Inflammatory-Markers-Between-Icosapent-Ethyl-and-Placebo.html
https://www.gponline.com/nice-backs-lipid-lowering-fish-oil-drug-use-alongside-statins/article/1789637
https://www.globenewswire.com/news-release/2022/05/16/2443846/18362/en/Research-Presented-at-the-American-Heart-Association-s-Quality-of-Care-and-Outcomes-Research-QCOR-Scientific-Sessions-Indicate-Potential-for-VASCEPA-icosapent-ethyl-to-Reduce-Major.html
https://www.globenewswire.com/news-release/2022/05/03/2434529/18362/en/New-Analysis-Reveals-Icosapent-Ethyl-Significantly-Reduces-Risk-of-Major-Cardiovascular-Events-in-Patients-with-Prior-Myocardial-Infarction-Heart-Attack.html
https://www.globenewswire.com/news-release/2022/04/26/2429163/18362/en/Amarin-Partner-HLS-Therapeutics-Completes-Reimbursement-Negotiations-with-Pan-Canadian-Pharmaceutical-Alliance-pCPA-for-VASCEPA-icosapent-ethyl.html
https://www.globenewswire.com/news-release/2022/04/01/2414691/18362/en/Eicosapentaenoic-Acid-EPA-Combined-with-Widely-Used-Statins-Significantly-Reduced-Lipid-Oxidation-in-Model-Membranes.html
https://www.globenewswire.com/news-release/2022/03/21/2406707/18362/en/Latest-Research-Evaluating-VASCEPA-Icosapent-Ethyl-to-be-Presented-at-the-American-College-of-Cardiology-s-71st-Annual-Scientific-Session.html
https://www.globenewswire.com/news-release/2022/02/24/2391306/18362/en/JAMA-Publication-Highlights-VASCEPA-Icosapent-Ethyl-Cardiovascular-Risk-Reduction-Extends-to-Cost-Effectiveness-at-Patient-Level.html
https://www.globenewswire.com/news-release/2021/11/15/2334802/18362/en/Amarin-Reports-Subgroup-Data-from-REDUCE-IT-Highlighting-Benefits-of-VASCEPA-VAZKEPA-Icosapent-Ethyl-in-Patients-with-Prior-Peripheral-Artery-Disease-PAD-Presented-in-Rapid-Fire-Or.html
https://www.globenewswire.com/news-release/2021/09/22/2301438/18362/en/Amarin-Outlines-New-Go-to-Market-Strategy-to-Accelerate-VASCEPA-Icosapent-Ethyl-Growth-in-U-S.html
https://www.globenewswire.com/news-release/2021/08/31/2289060/18362/en/Amarin-Reports-Overview-of-Latest-Clinical-Research-Evaluating-VASCEPA-VAZKEPA-Icosapent-Ethyl-and-Eicosapentaenoic-Acid-EPA-Presented-at-ESC-Congress-2021-Organized-by-the-Europea.html
https://www.globenewswire.com/news-release/2021/08/23/2284473/18362/en/Amarin-Reports-Data-from-REDUCE-IT-Showing-VASCEPA-VAZKEPA-Icosapent-Ethyl-Significantly-Reduces-Ischemic-Events-in-Patients-with-Prior-Heart-Attacks-Presented-in-Late-Breaking-Sci.html
https://www.globenewswire.com/news-release/2021/08/16/2280956/18362/en/Latest-Clinical-Research-Evaluating-VASCEPA-VAZKEPA-Icosapent-Ethyl-in-Patients-with-Residual-Cardiovascular-Risk-to-be-Presented-at-ESC-Congress-2021-Organized-by-the-European-Soc.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209437
https://www.reuters.com/business/healthcare-pharmaceuticals/us-supreme-court-denies-amarins-bid-revive-vascepa-drug-patents-2021-06-21/
https://investor.amarincorp.com/news-releases/news-release-details/clinical-data-and-other-research-results-regarding-vascepar
http://www.pharmafile.com/news/576626/mhra-gives-green-light-new-cardiovascular-treatment
Market Place
Share 
